奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌:PROpel试验的药代动力学数据
PROpel是一项阳性3期试验,显示奥拉帕利联合阿比特龙较安慰剂联合阿比特龙一线治疗转移性去势抵抗性前列腺癌可临床显著改善影像学无进展生存期。本分析在部分PROpel患者中测定奥拉帕利、阿比特龙及Δ4-阿比特龙的稳态血药浓度,评估两药是否存在临床相关药物相互作用。结果显示奥拉帕利与阿比特龙的稳态药代动力学参数与单药试验相当,两治疗组间阿比特龙稳态暴露量相似,联合奥拉帕利时Δ4-阿比特龙稳态暴露量略低;结果与既往2期研究一致,支持两药以各自完整单药剂量联用时未发生临床相关药代动力学药物相互作用的结论。
要点
- 奥拉帕利与阿比特龙稳态药代动力学参数与各自单药试验相当。
- 两治疗组间阿比特龙稳态暴露量相似。
- 联合奥拉帕利时Δ4-阿比特龙稳态暴露量略低。
核心结论
- 奥拉帕利与阿比特龙以各自完整单药剂量联用时未发生临床相关药代动力学药物相互作用。
- 结果与既往2期研究一致。
研究设计与样本
- PROpel(NCT03732820)为3期试验,本分析在部分PROpel患者中于给药前及给药后多个时间点采集血样,测定奥拉帕利、阿比特龙及Δ4-阿比特龙的稳态浓度。
主要发现
- 奥拉帕利与阿比特龙的稳态药代动力学参数与单药试验相当。
- 阿比特龙稳态暴露量在两治疗组间相似。
- 联合奥拉帕利时Δ4-阿比特龙稳态暴露量略低。
临床怎么用
- 作者认为奥拉帕利与阿比特龙以各自完整单药剂量联用时未发生临床相关药代动力学药物相互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PROpel (NCT03732820) was a positive phase 3 trial that demonstrated a clinically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in first-line metastatic castration-resistant prostate cancer. For a subset of PROpel patients, steady-state concentrations of olaparib, abiraterone, and Δ4-abiraterone were measured in blood samples collected before and at several time points after dose administration. The pharmacokinetics (PK) for each drug and metabolite were evaluated to determine whether any clinically relevant drug-drug interactions between olaparib and abiraterone occurred. The results demonstrate that steady-state PK parameters for olaparib and abiraterone in PROpel were comparable with those in monotherapy trials. Abiraterone steady-state exposures were similar between treatment arms. Δ4-Abiraterone had slightly lower steady-state exposures when abiraterone was administered in combination with olaparib. These results are consistent with a previous phase 2 study, supporting the conclusion that no clinically relevant PK-based drug-drug interactions occurred when olaparib and abiraterone were given in combination at their full monotherapy doses. PATIENT SUMMARY: When drugs are administered in combination, a key consideration is whether there are any interactions between the drugs that may affect their activity. We analyzed blood concentrations of olaparib and abiraterone in a subset of patients with prostate cancer from the PROpel trial to determine if there were interactions between these two drugs. We found that there was no significant effect on the profile of either drug when they were given together at the same doses used when each drug is given individually.
引用
- Armstrong AJ, Clarke N, Oya M, et al. Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial. Eur Urol Oncol. 2023. PMID: 39492050. doi:10.1016/j.euo.2023.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。